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Introduction
Before the current era of computed tomography (CT),
pulmonary parenchymal involvement with lymphoma
was reported in 11.6% of patients with Hodgkin disease
(HD) and 3.7% of patients with non-Hodgkin lym-
phoma (NHL) [1]. More recent CT-based studies
reported that 8% of HD patients had pulmonary
parenchymal disease at diagnosis [2, 3] and 12% at
recurrence [3]. These three study populations all in-
cluded a majority of adult patients. There are no reports
in the literature assessing the prevalence of pulmonary
parenchymal lymphoma in a purely pediatric popula-
tion.
HD and NHL together account for approximately
15% of pediatric malignancies. The typical presentation,
natural history, and treatment modalities of these
diseases are well established. Recently, the increasing
sophistication and success of pediatric organ trans-
plantation has brought with it an increase in the inci-
dence of post-transplant lymphoproliferative disorder
(PTLD). This entity is less well understood, but has been
reported to differ substantially from the spontaneously
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Abstract Background: The preva-
lence of pulmonary lymphoma in
the pediatric age group is not
documented in the literature.
Objective: This study was designed
to assess the prevalence of pulmo-
nary parenchymal lymphoma in
children with Hodgkin disease (HD),
non-Hodgkin lymphoma (NHL)
and post-transplant lymphoprolifer-
ative disorder (PTLD). Materials
and methods: A 10-year retrospec-
tive analysis of 161 lymphoma
patients (62 girls and 99 boys), mean
age of 12.4 years, was performed.
The definition of pulmonary lym-
phoma excluded those with isolated
pleural disease and/or mediastinal
adenopathy. Results: Eighty-two
patients had HD, 65 had NHL, and
14 had PTLD. Overall prevalence of
pulmonary parenchymal involve-
ment was 13% (21/161), including
12% of patients with HD, 10% of
patients with NHL, and 29% of
patients with PTLD. CT findings
included: pulmonary nodules (90%)
or mass (38%); interstitial (9%) or
alveolar (9%) disease; cavitation
(9%); and pleural based mass (9%).
Conclusions: Pulmonary parenchy-
mal disease in our pediatric lym-
phoma population was more
prevalent than expected (13%). This
is significant for patient manage-
ment. New pulmonary lesions in
patients with known lymphoma
should be regarded with suspicion.
In the setting of immune suppres-
sion, pulmonary lesions treated as
infection may actually represent
lymphoma. Expeditious biopsy of
lesions failing to respond promptly
to antibiotic therapy should be con-
sidered.
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treatment [4]. The majority of PTLD cases are associ-
ated with Epstein-Barr virus (EBV) infection, particu-
larly primary EBV infection in patients who were EBV
seronegative before transplantation [4]. Similar to NHL,
abdominal and thoracic clinical presentations are the
most common [4, 5].
Pulmonary parenchymal involvement in the pediat-
ric population with lymphoma has not been specifically
quantified in the era of CT. We have observed that a
diagnostic dilemma emerges when a patient who has
either known lymphoma or immune suppression pre-
sents with pulmonary disease. The presentations of
pulmonary parenchymal lymphoma are varied, the
index of suspicion may be low, and the pulmonary
disease may be attributed to the more common etiology
of infection [5, 6]. The purpose of this study was to
examine the prevalence of pulmonary parenchymal
involvement in the pediatric lymphoma population at
our institution (a tertiary care childrens hospital),
and to determine whether any differences in frequency
of pulmonary disease existed among the lymphoma
subgroups.
Materials and methods
IRB approval was obtained for retrospective analysis of the pedi-
atric lymphoma population at our institution during a 10-year
period, including review of hospital charts, pathology reports, and
CT studies. The radiology information database was searched for
the keyword lymphoma in patients under the age of 18 years at
the time of examination. We also ran a list of all children with
gallium scans at this institution. The entire list was then cross-
referenced with the pediatric oncology list of lymphoma patients.
We believe we captured all the pediatric lymphoma patients. In
total, 161 children with lymphoma (62 girls and 99 boys) with a
mean age of 12.4 years (range 1–20 years) were identified.
Chest CT images were reviewed by the primary author and one
or both pediatric radiologist coauthors. The chest CT protocol for
evaluation of the child with known or suspected lymphoma con-
sisted of axial or helical acquisition of images at 5-, 7-, or 10-mm
thickness depending on the age and size of the patient. Except in
cases of renal failure, all studies were performed with intravenously
administered contrast medium (2 cc/kg to a maximum of 75 cc).
Staging CT included a minimum of chest, abdomen, and pelvis CT,
and depending on the clinical presentation, neck and head CT were
occasionally added. Follow-up CT of the chest was obtained in
those patients with chest involvement at diagnosis or clinical sus-
picion of new intrathoracic disease. CT findings were categorized
based on the most frequent manifestations of pulmonary lym-
phoma described in the radiologic literature [5]: nodule (<1 cm);
mass (>1 cm); cavitation; alveolar (definition used was air-space
disease), and interstitial disease (definition used was bronchovas-
cular thickening); pleural based mass; pleural effusion; hilar or
mediastinal lymphadenopathy. Some of the patients had more than
one manifestation of pulmonary lymphoma.
Patients were divided into HD, NHL, and PTLD groups
based on medical record review and further subdivided according
to the presence or absence of biopsy-proven pulmonary paren-
chymal disease. Our criteria for PTLD required malignant
monoclonal lymphoproliferative disease with definitive tissue
diagnosis. Our definition of pulmonary lymphoma excluded those
patients with isolated pleural disease and/or isolated mediastinal
lymphadenopathy. The chi-square test was used for statistical
analysis.
Results
Eighty-two patients (51%) had HD, 65 (40%) had
NHL, and 14 (9%) had PTLD. Of the PTLD patients,
12 had non-Hodgkin type lymphoproliferative disease
and one had Hodgkin type. One additional patient had
an atypical monoclonal B cell lymphoproliferative
disorder related to congenital immune deficiency (Evans
syndrome). This patient was included in the PTLD
group because his lymphoproliferative disorder arose
in the setting of immunosuppression. Among the 12
transplants, there were six livers, five hearts, one kidney,
and one bone marrow transplant. Bone marrow is by
far the most common pediatric transplantation proce-
dure at our institution. Although a few pediatric lung
transplant patients are followed here, none appeared in
our PTLD population.
The sites of lymphoma involvement in all patients
were tabulated. Fifty-five of 82 (67%) patients with
HD, 32 of 65 (49%) patients with NHL, and 4 of 14
(29%) PTLD patients had entirely node-limited disease
(at both presentation and recurrence, when applicable).
The distribution of extranodal disease varied widely,
including: bone, bone marrow, eye, kidney, lung
parenchyma, mucosa-associated lymphoid tissue, par-
otid gland, pleura, skin, spleen, and thyroid gland.
Among PTLD patients, the site of lymphomatous
involvement was related to transplant site: five of five
cardiac transplant patients had only supradiaphrag-
matic disease and four of six hepatic transplant pa-
tients had only infradiaphragmatic disease. The single
renal transplant patient had only infradiaphragmatic
disease.
Overall, 26 patients had lung or pleural findings on
CT at some point during their therapeutic course. Three
had pleural effusions without pulmonary parenchymal
disease, one of which was lymphomatous by thoracen-
tesis. These patients were not included in the pulmonary
lymphoma group. One had pulmonary nodules which
resolved after antibiotic therapy; another died of respi-
ratory failure before a biopsy specimen was obtained.
These patients were also excluded.
Nineteen patients underwent lung biopsies, all of
which were positive for lymphoma. One patient had
multiple pulmonary nodules unresponsive to antibiot-
ics that regressed after chemotherapy; another had
massive pulmonary disease in the setting of a fatal
multisystem lymphoma recurrence and was presumed
by clinicians to have had pulmonary parenchymal
lymphoma. These 21 patients were included in the
pulmonary lymphoma group. In 16 children the
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diagnosis of pulmonary lymphoma was at presenta-
tion, in two children during the initial presentation
with progressive disease, and in 3 additional children
at relapse.
Thus, the overall prevalence of pulmonary paren-
chymal involvement in our lymphoma population was
13% (21/161). This included 12% (10/82) of patients
with HD, 10% (7/65) of patients with NHL, and 29%
(4/14) of patients with PTLD.
The Chi-square test was used to examine the rela-
tionship between the prevalence of pulmonary paren-
chymal involvement in the PTLD population and the
spontaneously arising lymphoma population (both
HD and NHL). The results did not indicate a signifi-
cant difference in the frequency of pulmonary paren-
chymal disease between the two groups of children
(P=0.19).CT findings in patients with pulmonary
involvement included: solitary or multiple pulmonary
nodules (90%), pulmonary mass (38%), interstitial (9%)
or alveolar (9%) disease, cavitation (9%), pleural based
mass (9%), pleural effusion (9%), and mediastinal
adenopathy (67%) (tabulated in Table 1). Findings are
shown in (Figs. 1, 2, 3, 4). Most patients had at least
two findings. No differences in the CT pattern of lung
disease were observed between the PTLD and sponta-
neously arising lymphoma groups.
Nine of the 21 patients had a gallium scan at the
time of diagnosis of the pulmonary lymphoma. One of
these was positive in the lung and a second was positive
in the pleural space; the other seven were negative in
the lungs.
The prevalence of specific areas of extrapulmonary
involvement was assessed in both the pulmonary lym-
phoma group as a whole and the remaining lymphoma
patients. This included tabulation of sites of nodal dis-
ease and extranodal involvement. No significant differ-
ences existed between the two groups. Apart from the
preferential distribution with respect to the diaphragm
in PTLD patients discussed above, there was no dem-
onstration of tropism between various sites of involve-
ment.
Discussion
Pulmonary parenchymal disease was more common in
all subsets of our pediatric lymphoma population than
has previously been reported [5]. In fact, the specific
incidence of pulmonary parenchymal involvement in
children, whether in spontaneously arising lymphoma or
PTLD, has not been well quantified. We observed more
frequent pulmonary parenchymal involvement in the
PTLD population than in children with spontaneously
arising lymphoma. However, the difference was not










Nodule 19/21 90% 19/31 61%
Mass 8/21 38% 21/31 68%
Interstitial +
alveolar
4/21 19% 11/31 35%
Cavitation 2/21 9% 10/31 32%
Pleural mass 2/21 9% 17/31 42%
Effusion 2/21 9% 13/31 42%
Mediastinal
adenopathy
14/21 67% 11/31 35%
aFrom [5]
Fig. 1 The definition of pulmonary parenchymal involvement
excluded those with findings limited to pleural effusion (P) and/
or mediastinal adenopathy (A). This 17- year-old boy with NHL
was included because he had additional pulmonary parenchymal
lymphoma, indicated by the arrow
Fig. 2 A 16- year-old boy with NHL with multiple pulmonary
masses (>1 cm) and nodules (<1 cm)
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statistically significant, probably due to the small size of
our PTLD population. The overall prevalence of pul-
monary lymphoma was 13%. Similar to the adult-based
data (Table 1), pulmonary nodules and pulmonary
masses were the most common findings. As noted in this
previous study, the absence of mediastinal adenopathy
on CT scan does not exclude the diagnosis of pulmonary
lymphoma.
Several reports in the literature have linked pulmo-
nary parenchymal PTLD directly to lung transplanta-
tion, while others have disputed this relationship [7].
However, such a relationship would not explain the
greater than expected prevalence of lung findings in our
PTLD population, as none of the children in our series
had undergone lung transplantation. In fact, it is prob-
able that our findings actually underestimate the prev-
alence of pulmonary parenchymal involvement in PTLD
(due to the small number of lung transplants followed at
our institution).
Bias in this study includes our restriction of the
diagnosis in pulmonary lymphoma to those with a chest
CT scan. In some children there may have been pul-
monary lymphoma evident solely on chest radiographs.
Additional bias may have been introduced in our re-
stricted definition of pulmonary lymphoma. Some of the
children with pulmonary lymphoma may not have had a
biopsy or may have died before demonstrating response
to therapy. It has been suggested that the increased
prevalence of pulmonary lymphoma in children is a di-
rect result of relapse and longer survival in this era of
chemotherapy. Our population had a marked predomi-
nance of pulmonary lymphoma at presentation, 16 of
the 21 cases. In an additional two children the pulmo-
nary lymphoma was diagnosed in progressive disease
with no remission. There were only three children in
whom the diagnosis of pulmonary lymphoma was made
at relapse.
The clinical implications of these findings are sig-
nificant. In the setting of immune suppression (whe-
ther related to organ transplant or secondary to
chemotherapy) new pulmonary parenchymal disease is
often treated empirically as infection. The present
series suggests that such lesions may represent pul-
monary parenchymal lymphoma. Therefore, pulmo-
nary disease failing to respond promptly to antibiotic
therapy deserves consideration of biopsy for definitive
tissue diagnosis. Pulmonary parenchymal disease in
lymphoma appears to be more prevalent than previ-
ously noted in the predominantly adult literature,
suggesting that new pulmonary disease in all pediatric
lymphoma patients should be regarded with height-
ened suspicion.
Fig. 4 This 15- month-old boy with PTLD has masses as well as
alveolar and interstitial pulmonary lymphoma. The mass (arrow) in
the right lung with the fluid level was thought to represent a
secondary abscess or pneumatocele
Fig. 3 This 12- year-old boy with HD has interstitial lymphoma
and nodules, one of which is included on this image (arrowhead)
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